Avastin

(Bevacizumab)

ApprovedMonoclonal antibody

Bevacizumab is used to treat certain cancers by blocking the growth of new blood vessels that feed tumors, which helps stop cancer cells from growing and spreading.[2] Avastin is currently approved and in use across 165 indications[4].[1]

Avastin is one of 1592 biologic programs targeting Colorectal Cancer. It is currently in Approved.

165

Indications

2,046

Total Trials

Active Trials

1,591

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Colorectal CancerTerminated

Endometrial CancerUnknown status

NeuroblastomaActive, not recruiting

Low Grade GliomaCompleted

Colorectal CarcinomaSuspended

Gastric CancerUnknown status

Breast CancerWithdrawn

MetastasisCompleted

RhabdomyosarcomaCompleted

Ovarian NeoplasmsNot yet recruiting

Colorectal CancerApproved

Terminated

Endometrial CancerPhase 2

Unknown status

NeuroblastomaPhase 2

Active, not recruiting

Low Grade GliomaPhase 2

Completed

Colorectal CarcinomaPhase 3

Suspended

Gastric CancerPhase 3

Unknown status

Breast CancerApproved

Withdrawn

MetastasisPhase 2

Completed

RhabdomyosarcomaPhase 2

Completed

Ovarian NeoplasmsPhase 3

Not yet recruiting

Showing 10 of 164 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Avastin

Lexiscan

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Metastatic Colorectal Cancer

NCT04854668

Q1 2027

Phase 1/2Recruiting

Metastatic Colorectal Cancer

NCT04689347

Q3 2027

Phase 2/3Not yet recruiting

Hepatocellular Carcinoma

NCT05976568

Phase 2Recruiting

Frozen Shoulder

NCT06976671

Phase 2Recruiting

Ovarian Cancer

NCT06083844

Q4 2027

Phase 2Not yet recruiting

Ovarian Cancer

NCT06063070

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer25 trials

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)

Completed· Roche logo

Roche·Phase 2·NCT02291289·1,044 enrolled

Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment

Terminated·—·Phase 2·NCT00717990·15 enrolled

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Active, not recruiting· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04854668·748 enrolled

Show 22 more trials

Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Recruiting·SShanghai Zhongshan Hospital·Phase 1·NCT06225622·78 enrolled

Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Recruiting·DDominik Paul Modest·Phase 2·NCT05007132·153 enrolled

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

Recruiting·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 1/2·NCT04689347·27 enrolled

A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 2·NCT00118755·435 enrolled

Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00077298·70 enrolled

Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer

Completed·—·Phase 2·NCT00165568·20 enrolled

Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases

Not yet recruiting·UUNICANCER·Phase 2·NCT07359456·130 enrolled

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

Not yet recruiting· Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.·Phase 1/2·NCT07391566·99 enrolled

A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer

Terminated· Roche logo

Roche·Phase 2·NCT02141295·197 enrolled

Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT01279681·32 enrolled

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 2·NCT00636610·199 enrolled

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Completed· Amgen logo

Amgen·Phase 2·NCT00819780·285 enrolled

A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 1·NCT00671372·42 enrolled

Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer

Unknown status·SSun Yat-sen University··NCT01912443·600 enrolled

Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)

Completed·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT00265824·700 enrolled

AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07021950·130 enrolled

Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

Completed·LLudwig-Maximilians - University of Munich·Phase 3·NCT02934529·673 enrolled

Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.

Active, not recruiting·GGruppo Oncologico del Nord-Ovest·Phase 1/2·NCT04564898·48 enrolled

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

Not yet recruiting·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT07150403·74 enrolled

Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer

Terminated·SSwiss Cancer Institute·Phase 3·NCT00544700·265 enrolled

BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00904839·128 enrolled

First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer

Completed·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT01163396·57 enrolled

Breast Cancer17 trials

A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT00960960·71 enrolled

A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel

Completed·TTheodoros Foukakis·Phase 2·NCT01722968·33 enrolled

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

Unknown status·MMemorial Sloan Kettering Cancer Center·N/A·NCT00436709·75 enrolled

Show 14 more trials

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00281528·208 enrolled

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

Terminated· Amgen logo

Amgen·Phase 2·NCT00356681·282 enrolled

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Completed·GGeron Corporation·Phase 2·NCT01256762·166 enrolled

ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer

Unknown status·PPremiere Oncology·Phase 2·NCT00404404·35 enrolled

Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer

Not yet recruiting·WWang Jiayu·Phase 2·NCT06539559·60 enrolled

Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer

Terminated·IInstitut Curie·Phase 1·NCT02250118·1 enrolled

Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases

Unknown status·HHenan Cancer Hospital·Phase 2·NCT05357417·100 enrolled

Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer

Unknown status·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT04739670·31 enrolled

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00915603·113 enrolled

Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00028990·722 enrolled

A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

Unknown status· Roche logo

Roche·Phase 3·NCT00262067·1,237 enrolled

Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00392392·29 enrolled

Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy

Unknown status·LLiNanlin,Ph.D, Chief Physician,Clinical Professor··NCT01652560·50 enrolled

A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT01201265·40 enrolled

Non-Small Cell Lung Cancer14 trials

Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

Terminated·UUniversity of California, San Francisco·Phase 2·NCT00293332·1 enrolled

Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT00411593

Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

Completed·UUniversity of Chicago·Phase 2·NCT00025389·8 enrolled

Show 11 more trials

Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Terminated·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00438204·39 enrolled

A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab

Completed· Amgen logo

Amgen·Phase 2·NCT00508625·213 enrolled

Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00976677·10 enrolled

A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer

Completed·BBiocad·Phase 3·NCT01763645·353 enrolled

Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00550537·116 enrolled

Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer

Completed·SStanford University·Phase 2·NCT00323869·48 enrolled

A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy

Completed· Roche logo

Roche·Phase 3·NCT01364012·276 enrolled

Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00541099·11 enrolled

Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

Unknown status·TThe Netherlands Cancer Institute·Phase 3·NCT02743923·203 enrolled

Study of Participants With Advanced Non-Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00948675·361 enrolled

Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00807573·44 enrolled

Colorectal Cancer11 trials

Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement

Terminated·WWashington University School of Medicine·Phase 2·NCT00537823·9 enrolled

5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

Unknown status·PPD Dr. med. Volker Heinemann·Phase 3·NCT00433927·568 enrolled

Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer

Withdrawn·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00571740

Show 8 more trials

Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00043004·119 enrolled

Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer

Completed·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT01022541·47 enrolled

Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients

Terminated·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT06332079·4 enrolled

Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis

Not yet recruiting·FFudan University··NCT05354674·302 enrolled

Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00438737·100 enrolled

First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer

Terminated·BBinhui Biopharmaceutical Co., Ltd.·Phase 2·NCT05648006·7 enrolled

TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer

Completed· Sanofi logo

Sanofi·Phase 2·NCT00399750·373 enrolled

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06540326·100 enrolled

Diabetic Macular Edema9 trials

Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema

Completed·MMaturi, Raj K., M.D., P.C.·Phase 4·NCT01309451·40 enrolled

The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema

Unknown status·SShahid Beheshti University of Medical Sciences·Phase 2/3·NCT02645734·133 enrolled

Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular Edema

Completed·UUniversity of Sao Paulo·N/A·NCT02310295·45 enrolled

Show 6 more trials

Unilateral Bevacizumab for Bilateral Diabetic Macular Edema

Withdrawn·AAsociación para Evitar la Ceguera en México·Phase 4·NCT00496405

Intravitreal Bevacizumab for Diabetic Macular Edema

Unknown status·—·Phase 2/3·NCT00703235

Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema

Withdrawn·UUniversity of California, San Francisco·Phase 2/3·NCT02229175

Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema

Enrolling by invitation·—·N/A·NCT07338097·116 enrolled

Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema

Completed·—·Phase 4·NCT02036424·45 enrolled

Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema

Unknown status·SShahid Beheshti University of Medical Sciences·Phase 1·NCT00999791

78 more indications

Ovarian Cancer9 trials

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT06063070·44 enrolled

Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer

Completed·—·Phase 2·NCT02022917·22 enrolled

Bevacizumab and Carboplatin for Patients With Ovarian Cancer

Completed·VVejle Hospital·Phase 2·NCT00744718·73 enrolled

Show 6 more trials

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06083844·20 enrolled

Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

Completed·VVejle Hospital·Phase 2·NCT04175470·20 enrolled

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

Completed·TTesaro, Inc.·Phase 2·NCT05751629·41 enrolled

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

Terminated·—·Phase 1·NCT01312376·18 enrolled

Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 3·NCT01802749·406 enrolled

Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab

Unknown status·NNational Cancer Institute, Naples·Phase 4·NCT01706120·400 enrolled

Bevacizumab7 trials

First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC

Completed·MMedSIR·Phase 2·NCT04408118·100 enrolled

A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects

Completed·SShanghai Institute Of Biological Products·Phase 1·NCT04135898·88 enrolled

Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations

Completed·JJohns Hopkins University·Phase 1·NCT01777412·10 enrolled

Show 4 more trials

Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema

Terminated·HHospital Clinic of Barcelona·Phase 3·NCT01095809·5 enrolled

PRP vs Bevacizumab for PDR Treatment

Completed·MMarashi Eye Clinic·Phase 2/3·NCT02705274·30 enrolled

CRLX101 Plus Bevacizumab in Advanced RCC

Completed·—·Phase 1·NCT01625936·22 enrolled

Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00941499·140 enrolled

Hepatocellular Carcinoma5 trials

Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Recruiting·—·Phase 2·NCT05528952·105 enrolled

A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Unknown status·—·N/A·NCT06233994·30 enrolled

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

Recruiting·TThe Methodist Hospital Research Institute·Phase 4·NCT05185505·24 enrolled

Show 2 more trials

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2/3·NCT05976568·668 enrolled

Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma

Terminated·UUniversity Hospital, Grenoble·Phase 2·NCT05448677·3 enrolled

Pancreatic Cancer5 trials

Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00100815·50 enrolled

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT00253526

Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

Withdrawn·RRoswell Park Cancer Institute·N/A·NCT00524069

Show 2 more trials

Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer

Terminated·MMassachusetts General Hospital·Phase 1/2·NCT00307723·52 enrolled

Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00088894·590 enrolled

Glioblastoma4 trials

Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma

Completed·—·Phase 1·NCT02768389·18 enrolled

Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients

Active, not recruiting·TTME Pharma AG·Phase 1/2·NCT04121455·117 enrolled

Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy

Terminated·CCortice Biosciences, Inc.·Phase 2·NCT02047214·17 enrolled

Show 1 more trial

A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00762255·19 enrolled

Lung Cancer4 trials

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

Completed· Pfizer logo

Pfizer·Phase 2·NCT00600821·118 enrolled

Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT01705184·120 enrolled

Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer

Completed·—·Phase 2·NCT02054052·22 enrolled

Show 1 more trial

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

Completed·UUniversity of Utah·Phase 1·NCT00708448·26 enrolled

Glioblastoma Multiforme4 trials

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Completed·SStemline Therapeutics, Inc.·Phase 1/2·NCT02078648·74 enrolled

A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme

Completed·RRigshospitalet, Denmark·Phase 2·NCT00800917·12 enrolled

Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00621686·54 enrolled

Show 1 more trial

Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme

Unknown status·GGlobal Neurosciences Institute·Phase 1·NCT02285959·30 enrolled

Pterygium3 trials

Outpatient Performed Pterygium Surgery Study

Withdrawn·UUniversity of California, San Francisco·Phase 4·NCT03037736

Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery

Completed·TThe University of Texas Health Science Center, Houston·Phase 2·NCT01115517·51 enrolled

Bevacizumab Injection for Recurrent Pterygium

Completed·IInstituto de Oftalmología Fundación Conde de Valenciana··NCT02007174·38 enrolled

Advanced Solid Tumors2 trials

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 2·NCT06895928·400 enrolled

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Terminated·NNewLink Genetics Corporation·Phase 1·NCT02648711·41 enrolled

Primary Peritoneal Cancer2 trials

Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Unknown status·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 3·NCT04679064·427 enrolled

Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Terminated·UUConn Health·Phase 2·NCT00408070·5 enrolled

Glaucoma2 trials

Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma

Completed·AAthens Vision Eye Institute·Phase 2/3·NCT02901236·40 enrolled

Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?

Completed·WWills Eye·Phase 2/3·NCT00853073·63 enrolled

Liver Metastases2 trials

Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases

Completed·EEPS Corporation·N/A·NCT01834014·110 enrolled

Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases

Completed·EEPS Corporation·Phase 2·NCT01836653·122 enrolled

Hereditary Hemorrhagic Telangiectasia2 trials

North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Completed·JJames Gossage·Phase 2·NCT01408030·123 enrolled

The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia

Completed·HHospices Civils de Lyon·Phase 1·NCT01507480·42 enrolled

Fallopian Tube Cancer2 trials

Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer

Terminated·—·Phase 2·NCT00866723·5 enrolled

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02121990·17 enrolled

Endometrial Cancer2 trials

A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT07054567·96 enrolled

Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01005329·34 enrolled

Cervical Cancer2 trials

A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Active, not recruiting·AAkeso·Phase 3·NCT04982237·445 enrolled

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

Terminated·UUniversity of Miami·Phase 2·NCT03367871·17 enrolled

Retinal Vein Occlusion2 trials

Bevacizumab for Central Retinal Vein Occlusion Study

Completed·AAnders Kvanta·Phase 3·NCT00906685·60 enrolled

Minocycline to Treat Central Retinal Vein Occlusion

Completed·NNational Eye Institute (NEI)·Phase 1/2·NCT01468844·6 enrolled

Small Cell Lung Cancer2 trials

A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)

Completed· Roche logo

Roche·Phase 2·NCT00403403·102 enrolled

Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer

Completed·HHellenic Oncology Research Group·Phase 2·NCT00755170·48 enrolled

Renal Cell Carcinoma2 trials

A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma

Terminated·UUniversity of Kansas Medical Center·Phase 1/2·NCT00934440·11 enrolled

Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:

Completed·—·Phase 1/2·NCT02348008·61 enrolled

Kidney Cancer2 trials

Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00684996·5 enrolled

Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00923130·30 enrolled

Solid Tumors2 trials

An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study

Completed· Roche logo

Roche·Phase 3·NCT02488330·12 enrolled

BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00095459·57 enrolled

Acute Myeloid Leukemia1 trial

Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00096148·120 enrolled

Systemic Therapy1 trial

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Not yet recruiting·TTempest Therapeutics·Phase 3·NCT06680258·740 enrolled

Gastrointestinal Tumors1 trial

A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.

Completed· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 1·NCT01916447·65 enrolled

Peritoneal Cancer1 trial

Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer

Completed·AAccelerated Community Oncology Research Network·Phase 2·NCT00407563·48 enrolled

Stage III Colon Cancer1 trial

Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00096278·2,710 enrolled

COVID-191 trial

Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT07089719·21 enrolled

Proliferative Diabetic Retinopathy1 trial

Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy

Completed·UUniversity of Campania Luigi Vanvitelli·Phase 4·NCT01025934

Performance Status1 trial

Trial of Poor Performance Status Patients (ToPPS)

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00892710·172 enrolled

Second-line Therapy1 trial

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Recruiting·RReplimune Inc.·Phase 2·NCT05733598·60 enrolled

Vestibular schwannoma1 trial

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT01767792·22 enrolled

Patients With Advanced Solid Tumors1 trial

Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00049088·24 enrolled

Lymphoma1 trial

S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00016094·60 enrolled

Liver Cancer1 trial

Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT00867321·24 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT01075464·64 enrolled

Metastatic Melanoma1 trial

Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma

Completed·HHaukeland University Hospital·Phase 2·NCT00139360·35 enrolled

First-line1 trial

A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

Not yet recruiting·BBiotheus Inc.·Phase 1/2·NCT06584071·140 enrolled

Melanoma1 trial

Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00466687·34 enrolled

Cervical Carcinoma1 trial

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT06241235·48 enrolled

Mucosal Melanoma1 trial

Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT02023710·182 enrolled

MPA1 trial

LUCAS (Lucentis Compared to Avastin Study)

Completed·OOslo University Hospital·Phase 4·NCT01127360·420 enrolled

Radiation Therapy1 trial

Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT01818973·45 enrolled

Observational Study1 trial

Multi-Centre, Observational Study on Safety of Bevacizumab Biosimilars in Clinical Practice Among Chinese Patients

Unknown status·—··NCT05009017·272 enrolled

Retinopathy1 trial

Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)

Completed·JJohann Wolfgang Goethe University Hospital·N/A·NCT00802906·12 enrolled

Uveal Melanoma1 trial

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

Terminated·AArman Mashayekhi·Phase 2·NCT01471054·6 enrolled

Rectal Cancer Patients1 trial

Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients

Completed·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT01554059·25 enrolled

Lenalidomide1 trial

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01183663·180 enrolled

Primary Peritoneal1 trial

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00085358·40 enrolled

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01130519·83 enrolled

Primary Brain Tumor1 trial

Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy

Completed·RRigshospitalet, Denmark·Phase 2·NCT00463203·54 enrolled

Non-Small Cell Lung Adenocarcinoma1 trial

A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01051934·2 enrolled

GAN1 trial

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Completed· Amgen logo

Amgen·Phase 2·NCT01327612·12 enrolled

Retinal Detachment1 trial

Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.

Completed·WWills Eye·N/A·NCT01860586·20 enrolled

Age-Related Macular Degeneration1 trial

Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)

Completed·JJohns Hopkins University·Phase 1·NCT00407719·10 enrolled

Locally Advanced or Metastatic NSCLC1 trial

Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC

Completed·HHellenic Oncology Research Group·Phase 2·NCT00620971·77 enrolled

Neovascular AMD1 trial

Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD

Completed·RRetinal Consultants Medical Group·Phase 2·NCT00426998·30 enrolled

Stage III Rectal Cancer1 trial

Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00052559·32 enrolled

Malignant Glioma1 trial

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

Completed·—·Phase 2·NCT00352521·20 enrolled

Recurrent or Refractory Solid Tumors1 trial

A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin

Completed·—·Phase 1·NCT00993044·13 enrolled

Tyrosine Kinase Inhibitors1 trial

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Unknown status·TThe University of Hong Kong·Phase 2·NCT03647956·40 enrolled

Multiple Myeloma1 trial

Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·CCalifornia Cancer Consortium·Phase 2·NCT00022607

Locally-advanced Rectal Cancer1 trial

A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer

Completed· Roche logo

Roche·Phase 2·NCT00865189·91 enrolled

Glioma1 trial

Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

Completed·NNational Cancer Institute (NCI)·Phase 2/3·NCT01236560·101 enrolled

Chemotherapy1 trial

QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

Recruiting·FFudan University·Phase 2·NCT06786026·60 enrolled

Absorption1 trial

Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye

Completed·QQueen's University·Phase 3·NCT01661946·10 enrolled

Trial1 trial

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

No longer available·TTracon Pharmaceuticals Inc.··NCT02354612

Postmenopausal Women1 trial

Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women

Completed·SSpanish Breast Cancer Research Group·Phase 3·NCT00545077·380 enrolled

Squamous Cell Carcinoma1 trial

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Terminated·MMassachusetts General Hospital·Phase 2·NCT00392665·36 enrolled

Colorectal Carcinoma1 trial

Study of Gamma Interfereon in Metastatic Colorectal Carcinoma

Completed·AAccelerated Community Oncology Research Network·Phase 2·NCT00786643·48 enrolled

Metastatic Solid Tumors1 trial

Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02665416·94 enrolled

Frozen Shoulder1 trial

A Study to Determine the Safety and Efficacy of Bevacizumab Administered Via Injection Into the Shoulder Joint of Participants With Adhesive Capsulitis (Frozen Shoulder)

Recruiting·MMacquarie University, Australia·Phase 2·NCT06976671·28 enrolled

Prostate Cancer1 trial

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Completed·—·Phase 2·NCT00776594·102 enrolled

Pediatric Solid Tumor1 trial

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Recruiting·SSt. Jude Children's Research Hospital·Phase 1/2·NCT05468359·64 enrolled

Gastric Cancer1 trial

Avastin and Taxotere for Esophagogastric Cancer

Completed·—·Phase 2·NCT00137813·42 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03193190·341 enrolled

Diabetic Macular Oedema1 trial

Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema

Completed·UUniversity of Sydney·Phase 2·NCT01298076·61 enrolled

Regulatory

FDA Approval Timeline[5]

Feb 26, 2004

AVASTIN

NDA BLA125085

Feb 26, 2004

Avastin

BLA 125085

Feb 26, 2004

AVASTIN

BLA BLA125085

Dec 22, 2004

AVASTIN

NDA BLA125085

Sep 29, 2005

AVASTIN

NDA BLA125085

Apr 18, 2006

AVASTIN

NDA BLA125085

Jun 20, 2006

AVASTIN

NDA BLA125085

Sep 21, 2006

AVASTIN

NDA BLA125085

Oct 11, 2006

AVASTIN

NDA BLA125085

Sep 20, 2007

AVASTIN

NDA BLA125085

Feb 22, 2008

AVASTIN

NDA BLA125085

Mar 10, 2008

AVASTIN

NDA BLA125085

Nov 4, 2008

AVASTIN

NDA BLA125085

May 5, 2009

AVASTIN

NDA BLA125085

Jul 31, 2009

AVASTIN

NDA BLA125085

Dec 28, 2010

AVASTIN

NDA BLA125085

Feb 8, 2011

AVASTIN

NDA BLA125085

Sep 30, 2011

AVASTIN

NDA BLA125085

Dec 20, 2011

AVASTIN

NDA BLA125085

Dec 21, 2011

AVASTIN

NDA BLA125085

Dec 21, 2011

AVASTIN

NDA BLA125085

May 3, 2012

AVASTIN

NDA BLA125085

Oct 26, 2012

AVASTIN

NDA BLA125085

Nov 20, 2012

AVASTIN

NDA BLA125085

Jan 23, 2013

AVASTIN

NDA BLA125085

Mar 26, 2013

AVASTIN

NDA BLA125085

Dec 16, 2013

AVASTIN

NDA BLA125085

Aug 14, 2014

AVASTIN

NDA BLA125085

Aug 30, 2014

AVASTIN

NDA BLA125085

Nov 14, 2014

AVASTIN

NDA BLA125085

May 7, 2015

AVASTIN

NDA BLA125085

Sep 29, 2015

AVASTIN

NDA BLA125085

Dec 1, 2015

AVASTIN

NDA BLA125085

Dec 6, 2016

AVASTIN

NDA BLA125085

Dec 5, 2017

AVASTIN

NDA BLA125085

Apr 30, 2018

AVASTIN

NDA BLA125085

Jun 13, 2018

AVASTIN

NDA BLA125085

Apr 3, 2019

AVASTIN

NDA BLA125085

Jun 20, 2019

AVASTIN

NDA BLA125085

May 29, 2020

AVASTIN

NDA BLA125085

Sep 30, 2020

AVASTIN

NDA BLA125085

Oct 9, 2020

AVASTIN

NDA BLA125085

Dec 9, 2020

AVASTIN

NDA BLA125085

Sep 18, 2022

AVASTIN

NDA BLA125085

Dec 6, 2023

AVZIVI TNJN

BLA BLA761198

Sources

References

[1]
ClinicalTrials.gov — 2046 trial records for Bevacizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Avastin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Bevacizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA BLA761198). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Vascular Endothelial Growth Factor a Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Roche

Avastin

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Metastatic Colorectal Cancer25 trials

Breast Cancer17 trials

Non-Small Cell Lung Cancer14 trials

Colorectal Cancer11 trials

Diabetic Macular Edema9 trials

Ovarian Cancer9 trials

Bevacizumab7 trials

Hepatocellular Carcinoma5 trials

Pancreatic Cancer5 trials

Glioblastoma4 trials

Lung Cancer4 trials

Glioblastoma Multiforme4 trials

Pterygium3 trials

Advanced Solid Tumors2 trials

Primary Peritoneal Cancer2 trials

Glaucoma2 trials

Liver Metastases2 trials

Hereditary Hemorrhagic Telangiectasia2 trials

Fallopian Tube Cancer2 trials

Endometrial Cancer2 trials

Cervical Cancer2 trials

Retinal Vein Occlusion2 trials

Small Cell Lung Cancer2 trials

Renal Cell Carcinoma2 trials

Kidney Cancer2 trials

Solid Tumors2 trials

Acute Myeloid Leukemia1 trial

Systemic Therapy1 trial

Gastrointestinal Tumors1 trial

Peritoneal Cancer1 trial

Stage III Colon Cancer1 trial

COVID-191 trial

Proliferative Diabetic Retinopathy1 trial

Performance Status1 trial

Second-line Therapy1 trial

Vestibular schwannoma1 trial

Patients With Advanced Solid Tumors1 trial

Lymphoma1 trial

Liver Cancer1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Metastatic Melanoma1 trial

First-line1 trial

Melanoma1 trial

Cervical Carcinoma1 trial

Mucosal Melanoma1 trial

MPA1 trial

Radiation Therapy1 trial

Observational Study1 trial

Retinopathy1 trial

Uveal Melanoma1 trial

Rectal Cancer Patients1 trial

Lenalidomide1 trial

Primary Peritoneal1 trial

Complication1 trial

Advanced NSCLC1 trial

Leiomyoma1 trial

Primary Brain Tumor1 trial

Non-Small Cell Lung Adenocarcinoma1 trial

GAN1 trial

Retinal Detachment1 trial

Age-Related Macular Degeneration1 trial

Locally Advanced or Metastatic NSCLC1 trial

Neovascular AMD1 trial

Stage III Rectal Cancer1 trial

Malignant Glioma1 trial

Recurrent or Refractory Solid Tumors1 trial

Tyrosine Kinase Inhibitors1 trial

Multiple Myeloma1 trial

Locally-advanced Rectal Cancer1 trial

Glioma1 trial

Chemotherapy1 trial